UNSPSC 51413402: Pildralazine

This classification denotes a vasodilating agent with the molecular formula C8H15N5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FU2BGC781U, chemically known as 3(2h)-pyridazinone, 6-((2-hydroxypropyl)methylamino)-, hydrazone but generally known as pildralazine, which bears US NIH Compound Identifier 68829. European Medicines Agency schedules Pildralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09833MIG.

UNSPSC 51413402 Pildralazine is a Commodity code that encompasses specific pharmaceutical products — in this case, the antihypertensive agent pildralazine — procured by state and local health systems, emergency medical services, and pharmacy benefit programs. State and local governments acquire these medications through direct sealed-bid procurement (as fire rescue services do), cooperative purchasing alliances, and therapeutic pharmacy initiatives that seek to optimize prescription fulfillment and cost management across multiple jurisdictions. The issuing bodies range from municipal fire departments and city purchasing offices to state health and human services agencies and multistate cooperative purchasing organizations, each sourcing medications for emergency response, institutional pharmacy, or employee health plans.

Recent activity shows three distinct procurement approaches in Florida, Texas, and Minnesota. The City of Tampa issued an IFB in April 2026 (due April 8, 2026) for Advanced Life Support Medications including specific vials and injections for Tampa Fire Rescue, with an estimated contract value of $40,000.00 and a one-year term plus renewal options, available to Small Local Business Enterprises under a 5 percent bid discount. Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling early-stage planning for direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with awards effective July 1, 2026, requiring vendors to maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act certifications.